Deal Notes: GlycoMimetics/Pfizer, Pharmacyclics/Servier, TG Therapeutics/Rhizen, Takeda/BioMotiv, Amherst/NovaDel

 
• By Mandy Jackson

Pfizer delays Phase III study with GlycoMimetics drug; Pharmacyclics, Servier end agreement; TG Therapeutics licenses drug from Rhizen; Takeda invests $25m in BioMotiv; and Amherst buys NovaDel's ZolpiMist.

More from Musculoskeletal

More from Therapy Areas